Ablynx's first inhaled nanobody successfully completes phase I study


ALX-0171 has the potential to become a first-in-class therapy.

GHENT, Belgium, 18 September 2012 - Ablynx [Euronext Brussels: ABLX] today announced that it has achieved positive results from a Phase I study with the first ever inhaled Nanobody, ALX-0171, a trivalent molecule which has been specifically designed by Ablynx for direct lung delivery, via a nebuliser, to treat respiratory syncytial virus (RSV) infections.

PDF-file 379.3kb